Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 13%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Veracyte is a leader in the rapidly growing market for next-generation diagnostic tests that utilize comprehensive genomic information to improve the diagnosis of cancer and other diseases. Their tests, including Decipher, Afirma, Prosigna, and Decipher Bladder, have shown strong sales growth and potential for continued expansion. With the company's solid financial position and multiple upcoming presentations and trials, it is likely that their revenue and earnings will continue to grow, making it a potentially strong investment opportunity.

Bears say

Veracyte is a genomic diagnostics company that offers tests for multiple types of cancer. While the company has potential growth opportunities in the MRD market and ongoing studies for its TrueMRD platform, its financials do not currently support a strong outlook. The company has a history of generating revenue and testing volume growth, but its revenue per test is only increasing slightly and it is not yet profitable. Additionally, the company's reliance on its urology sales channel and the competition in the MRD market may limit its growth potential and profitability in the future.

Veracyte (VCYT) has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 8 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.